Anuh Pharma Limited

ANUHPHRFair value region

A 6-pillar fundamental profile. Each pillar scored 0–10.

6.5/10 composite
Prism for ANUHPHR.NS: composite 6.5 of 10, verdict Fair value regionPULSEQUALITYMOATSAFETYGROWTHVALUEBelow cohort range—5.86.59.07.6Below cohort range—

Pulse

— · Neutral

Pulse data unavailable; neutral placeholder

Pulse tracks recent momentum in price, analyst revisions, and news sentiment. Higher means more positive near-term tailwinds.

Quality

5.8 · Moderate

Piotroski 5/9, ROCE 18.8%

Quality captures profitability, return on capital, and earnings consistency. Higher means a better business.

Moat

6.5 · Moderate

Narrow moat

Moat estimates durable competitive advantages — brand, scale, switching costs. Higher means more defensible.

Safety

9.0 · Strong

D/E 0.00, Int cov 99.4x

Safety looks at balance-sheet quality, leverage, and cash generation. Higher means lower financial risk.

Growth

7.6 · Strong

Rev CAGR 13.5%, EPS CAGR 15.7%

Growth reflects revenue and earnings expansion over recent years. Higher means faster compounding.

Value

— · Insufficient peer data

Only 0 MoS peers in cohort

Value measures how the stock's price compares to its intrinsic worth. Higher means more discount to fair value.

Compare with another stock

Overlay ANUHPHR's prism against a peer.

Share this prism

Share on XWhatsApp

Get the full analysis

Interactive DCF, sensitivity, peer comparison, and AI summary for ANUHPHR.

Full analysis →

Model estimate. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.